Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Halozyme (HALO)

Halozyme raises 2026 guidance after Q2 revenue rises 48% to $481 million

Positive Impact 4 of 5 guidance Written later

Halozyme reported second quarter 2026 total revenue of $481 million, up 48% from a year earlier, and GAAP diluted EPS of $1.90 versus $1.33. The company raised its full-year 2026 guidance for total revenue, royalty revenue, adjusted EBITDA and non-GAAP diluted EPS, and said it repurchased $333 million of shares in the quarter.

Key points

  • Q2 2026 total revenue $481.0 million vs. $325.7 million in Q2 2025; royalties $307.7 million, up 50%
  • Net income $229.9 million vs. $165.2 million; GAAP diluted EPS $1.90 vs. $1.33
  • 2026 non-GAAP diluted EPS guidance raised to $8.65-$9.00 from $7.75-$8.25; total revenue guidance raised to $1.835-$1.910 billion
  • Repurchased 4.8 million shares for $332.8 million at an average price of $69.30 in Q2 2026

The filing

CompanyHalozyme (HALO)
Form8-K, current report
Filed with the SECAug 6, 2026, 4:08 PM ET
Accession number0001159036-26-000103

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:12 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.